Monte Rosa Therapeutics
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $2,781 | $12,768 | $23,194 | $84,929 |
Gross Profit | 693 | 10,673 | 23,194 | 84,929 |
EBITDA | -47,627 | -28,163 | -13,429 | 46,084 |
EBIT | -49,715 | -30,258 | -15,554 | 44,036 |
Net Income | -46,135 | -27,081 | -12,295 | 46,885 |
Net Change In Cash | 2,781 | 12,768 | 23,194 | 84,929 |
Free Cash Flow | -43,781 | 99,777 | -36,415 | -47,079 |
Cash | 129,883 | 208,343 | 69,429 | 78,530 |
Basic Shares | 65,543 | 82,397 | 82,186 | 82,956 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $123,672 | $75,622 | $0 | $0 |
Gross Profit | 115,316 | 67,501 | -6,222 | -8,559 |
EBITDA | -45,852 | -72,991 | -137,089 | -108,639 |
EBIT | -54,208 | -81,112 | -143,311 | -112,384 |
Net Income | -38,626 | -72,700 | -135,352 | -108,501 |
Net Change In Cash | 123,672 | 75,622 | 0 | 0 |
Cost of Revenue | -291,219 | |||
Free Cash Flow | -27,498 | 38,008 | -62,843 | -105,377 |
Cash | 129,883 | 224,254 | 128,101 | 54,912 |
Basic Shares | 83,071 | 73,910 | 51,396 | 47,227 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | $0 |
2025-12-31 | -$0.55 |
2025-09-30 | -$0.33 |
2025-06-30 | -$0.15 |
